The U.S. Food and Drug Administration has recently implemented a new rule establishing a category for certain over-the-counter (OTC) drugs, known as additional conditions for nonprescription use (ACNU). This development allows certain prescription-only medications to become available OTC if specific criteria are met. The finalized rule creates an alternative pathway aimed at drugs with proven safety records, particularly those that are off-patent.
According to legal analysts, like those at Skadden, this shift can potentially benefit pharmaceutical companies with off-patent drugs by expanding accessibility while maintaining safety through the stipulated conditions. However, it’s important to note that transforming a prescription drug to an OTC status can entail additional expenses and requires thorough consideration of regulatory and market implications. For further exploration of this matter, the details are available in the original article from Law360.